Abstract:Key PointsMost human cancers exhibit a high degree of intratumour heterogeneity that arises from heritable and stochastic genetic and epigenetic changes, as well as environmental variations within the tumour. Heterogeneous subpopulations that exist within close proximity and compete for limited resources can engage in complex interactions that affect tumorigenesis, disease progression and therapeutic outcomes.Phenotypic changes that arise from subclonal interactions in heterogeneous tumours were observed by cancer biologists very early on. However, as studies mostly focused on cell-autonomous oncogenes and tumour suppressors, investigations into clonal interactions went under the radar for almost three decades. With the increasing recognition of intratumour heterogeneity fuelled by advances in technology, dissecting the mechanistic basis of clonal interactions is now gaining more attention.In addition to the more traditional models that explore clonal interactions strictly from the competitive angle, newer studies are investigating cooperative interactions among subclones that could give rise to novel characteristics and that potentially increase the growth and progression of the tumour.In the absence of proper tools to directly study clonal interactions in patient samples, studies in D. melanogaster, rodents and xenograft systems (using both established cell lines and patient-derived cells) are providing us with mechanistic insights into interclonal crosstalk.Theoretical and mathematical modelling are being used to simulate clonal dynamics under variable circumstances. Although currently far from perfect, these in silico cancer models have already been useful for the design of optimized cancer therapies for the more effective eradication of tumours.Cooperation can be metabolically costly but evolution and survival are more efficient, especially in a changing environment, when diversity and heterogeneity are high. Insights from patient tumours have revealed the presence of multiple independent neoplastic driver subclones that could re-establish tumour heterogeneity after therapy and lead to disease relapse. Furthermore, there is increasing evidence of transient clonal cooperation between neoplastic and benign subclones, which can also lead to tumour recurrence.In order to tackle the ever-evolving populations of tumour cells more effectively and to devise more lasting cures in patients, we must use ecological approaches that take advantage of cooperative tumour-promoting interactions and strategically eliminate them instead of targeting each individual subpopulation.

Beyond genetics: driving cancer with the tumour microenvironment behind the wheel

Cancer genome and tumor microenvironment: Reciprocal crosstalk shapes lung cancer plasticity

Genetic and Non-Genetic Mechanisms Underlying Cancer Evolution

Changing mutational and adaptive landscapes and the genesis of cancer

Role of the Tumor Microenvironment in Tumor Progression and the Clinical Applications (Review).

Tumor initiation and early tumorigenesis: molecular mechanisms and interventional targets

Concepts Collide: Genomic, Immune, and Microbial Influences on the Tumor Microenvironment and Response to Cancer Therapy

A tug-of-war between driver and passenger mutations in cancer and other adaptive processes

Epigenomic heterogeneity as a source of tumour evolution

Genetic Expression in Cancer Research: Challenges and Complexity

Characterizing the Ecological and Evolutionary Dynamics of Cancer

Tumorigenesis: it takes a village

Tumor microenvironment as a complex milieu driving cancer progression: a mini review

Ras drives malignancy through stem cell crosstalk with the microenvironment

Microenvironmental Regulation of Cancer Stem Cell Phenotypes

The Epigenetic Hallmarks of Cancer

Interplay between Solid Tumors and Tumor Microenvironment

Neo-Darwinian Principles Exemplified in Cancer Genomics

Tumor microenvironment: A playground for cells from multiple diverse origins

Abstract 5514: Crosstalk between prostatic epithelial cells and the tumor microenvironment drives cancer progression and metastasis

Plasticity and Tumor Microenvironment in Pancreatic Cancer: Genetic, Metabolic, and Immune Perspectives